The Claim
Administration of LEAP2 in humans reduces postprandial glucose levels and food intake to an extent similar to that of GLP-1.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When LEAP2 is given to humans, it lowers blood sugar after meals and decreases how much food people eat, with a similar effect to GLP-1.
See the scientific wording
LEAP2 administration in humans reduces postprandial glucose levels and food intake to a degree comparable to GLP-1, suggesting it has therapeutic potential for obesity and type 2 diabetes.
After eating, the liver and gut release LEAP2, which blocks a hunger signal called ghrelin in the brain and pancreas. This reduces hunger and increases insulin release, which lowers blood sugar. LEAP2 also directly boosts insulin production in the pancreas, helping the body clear sugar from the blood faster.
What the research says
1 studyStudy: The Ghrelin-LEAP2 System in Obesity and Diabetes: Pathophysiological Roles and Therapeutic Potential
Giving people a hormone called LEAP2 makes them eat less and lowers their blood sugar after eating, just like a known diabetes drug called GLP-1. This suggests LEAP2 could be a new treatment for obesity and diabetes.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.